For research to be applicable to all segments of the population, Swenor and her co-author, Jennifer Deal, Ph.D., M.H.S., assistant professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, say that guidelines for including people in specific studies should avoid ruling out people with disabilities.
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, with a manageable safety profile.
Making initiation of buprenorphine easy and timely was associated with a 25 percent increase in the likelihood of its use of treatment in Penn Medicine emergency departments
Generalized pustular psoriasis (GPP) is a rare, life-threatening skin condition for which there are no approved treatments. It is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus). There is a high unmet need for treatments that can rapidly and completely resolve the signs and symptoms of GPP flares. Flares greatly affect a person’s quality of life and can lead to hospitalization with serious complications, including heart failure, renal failure, sepsis, and death.
.jpg&width=400&height=400)
Axicabtagene ciloleucel, known by the brand name Yescarta, is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.
Although unproven, this novel sickle cell therapy serves as a potential cure. More measures need to be taken to determine long-term function and organ improvement.
Research Shows Vaccine Has 90 Percent Efficacy at Preventing Infections; Moderate to Severe Disease Occurred Only in Placebo Recipients
The anti-cancer effect of the drug may help those with rare, hereditary cancer syndromes avoid surgeries by shrinking tumors via a daily oral dose.
Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers. The cellular therapy uses a patient’s own immune cells that are reengineered to better seek out and destroy cancer cells. The single infusion treatment is approved for patients who have relapsed after two or more types of therapy but results from the ZUMA-7 clinical trial show lymphoma patients can benefit from receiving the CAR T product axicabtagene ciloleucel (Yescarta) sooner.
Investigators at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS) explored how Artificial Intelligence/Machine Learning will complement existing approaches focused on genome-protein sequence information, including identifying mutations in human tumors published online December 2 in The New England Journal of Medicine.
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in patients with renal cell carcinomas (RCC) and non-renal cell carcinoma neoplasms associated with von Hippel-Lindau (VHL) disease. The study was published today in the New England Journal of Medicine.
A new article published in The New England Journal of Medicine suggests that secondary antibodies known as “anti-idiotype antibodies” could be responsible for some of the side effects of COVID-19 vaccines and the symptoms of long-haul COVID.
A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction – or in some cases complete elimination – of painful and potentially life-threatening bleeding events, according to a new study led by researchers at Children’s Hospital of Philadelphia (CHOP). The results of the phase 1/2 trial, which were published today in the New England Journal of Medicine, are the first to demonstrate stable coagulation factor VIII in hemophilia A patients following gene therapy.
An international study of more than 400 adults concludes that people who undergo mitral valve surgery (between the left atrium and the left ventricle of the heart) and also have less than severe leakage of the tricuspid valve (a section of the heart that directs blood from the right atrium to the ventricle) may benefit from having both valves repaired at the same time.
.jpg&width=400&height=400)
Researchers compared milvexian with enoxaparin for prevention of blood clots in 1,242 patients from18 countries undergoing knee replacement surgery who were enrolled between June 2019 and February 2021.They found that at a total daily dose of 100 mg or more, milvexian resulted in better clot protection but no increase in bleeding compared with enoxaparin, the control drug. Milvexian was evaluated in daily doses ranging from 25 to 400 mg; there was no increase in bleeding over this wide range of doses.
In a new review article, published today in The New England Journal of Medicine, researchers from University Hospitals (UH), Case Western Reserve University and Boston College discuss evidence linking pollution and cardiovascular disease. The research team highlights strategies for reducing individual exposure to pollution, and the importance of government-supported interventions encouraging clean energy.
A commentary, published in the Nov. 3 issue of the journal NEJM Catalyst Innovations in Care Delivery, highlights how defects in surgical care could be diminished or eliminated for the benefit of patients and to lower costs in American health care spending. Using colorectal surgery to provide examples and national estimates of the costs of defects in surgical care, the paper summarizes a holistic approach to eliminating defects in surgical care and offers a framework for centers of excellence for removing them. The paper estimates that defects in colorectal surgery cost the American health care system more than $12 billion. The authors discuss eight areas (or domains) of defects that waste money and/or contribute to lower value in care for colorectal surgery patients.
SEATTLE — Nov. 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
Researchers published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored by Vir Biotechnology and GlaxoSmithKline. The study found that compared to the placebo group, COVID-19 patients who received sotrovimab had a significantly reduced risk of hospitalization or death and that the treatment, which was administered by intravenous infusion on an outpatient basis, was safe.
Research uncovers racial bias in oxygen readings during the COVID-19 pandemic, even amongst patients needing ECMO.
Vaccination is over 90 per cent effective at preventing deaths from the Delta variant of Covid-19, according to the first country-level data on mortality.
A new report finds women physicians across all races and ethnicities earn less than their male counterparts. This new data reinforces that academic medicine must find a better approach to how they pay physicians. The authors of a NEJM perspective lay out some potential solutions.
In a paper published in the New England Journal of Medicine, a team of experts at Beth Israel Deaconess Medical Center compared immune responses induced by the three COVID-19 vaccines over an eight-month follow-up period.
A cell-based influenza vaccine has effectively provided protection against the flu in children and adolescents, according to a new study.
Yale Cancer Center and Smilow Cancer Hospital experts explain why the PALB2 gene can increase your breast cancer risk.
Health care personnel who received a two-dose regimen of Pfizer–BioNTech vaccine had an 89% lower risk for symptomatic illness than those who were unvaccinated. For those who received the two-dose regimen of the Moderna vaccine, the risk was reduced by 96%.
International group of researchers identify new childhood genetic condition and a potential cure that can be delivered during pregnancy.
20240208171546.png&width=400&height=400)
New data published in the New England Journal of Medicine (NEJM) and featured at the European Society for Medical Oncology (ESMO) Congress 2021 highlights a promising new treatment for individuals with HER2-mutant non-small cell lung cancer (NSCLC).
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
Ischemic stroke patients treated on a mobile stroke unit (MSU) received anti-clot medication faster and ended up with less disability at 90 days, according to a study published today in the New England Journal of Medicine led by researchers at UTHealth Houston and Memorial Hermann-Texas Medical Center.
A study measured effectiveness of COVID-19 mRNA vaccines among health workers, most notably during the emergence of delta virus variant and coincident with end of state’s mask mandate, finding protection waned over time, dropping sharply 6-8 months after full vaccination.
Mount Sinai study is first to compare this anticoagulant with the standard of care in large randomized clinical trial
Moderately ill patients hospitalized with COVID-19 have better chances of survival if treated with therapeutic-dose anticoagulation, according to an international study involving 121 sites, including UT Southwestern Medical Center.
A NIH study co-led and designed by Michigan Medicine researchers found that using convalescent plasma to treat newly infected #COVID-19 patients demonstrated no significant benefit. The trial was stopped in February 2021 due to lack of efficacy based on planned interim analysis
The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo. The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group - after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.
The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo. The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group - after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.
In an article in the New England Journal of Medicine, scientists from Fred Hutchinson Cancer Research Center, Johns Hopkins Bloomberg School of Medicine, the U.S. Military HIV Research Program and the Institute for Global Health and Infectious Diseases at the University of North Carolina urged increased attention to persistent COVID-19 infections in immunocompromised people.
The investigators discovered that in moderately ill patients full-dose heparin reduced the need for organ support compared to those who received lower-dose heparin.
A potentially game-changing treatment for people with, or at risk of, blood clots has been found effective by an international team of researchers led by McMaster University. Results showed one abelacimab injection prevents blood clots for up to a month after surgery, reducing the risk by about 80%.
Children and adolescents with multisystem inflammatory syndrome in children (MIS-C) who are treated initially with intravenous immune globulin (IVIG) and glucocorticoids have reduced risk for serious short-term outcomes, including cardiovascular dysfunction, than those who receive an initial treatment of IVIG alone, a new study finds.
People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. For those few vaccinated people who do still get an infection, or “breakthrough” cases, the study suggests that vaccines reduce the severity of COVID-19 symptoms and shorten its duration.
A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time. The findings, reported online today in the New England Journal of Medicine, underscore the need for new drugs that inhibit KRAS differently than current agents do.
Blood sugar control among adults with diabetes in the United States declined significantly in the past decade, according to a nationwide study from researchers at the Johns Hopkins Bloomberg School of Public Health.
The treatment’s effectiveness was described in a report describing three Canadian patients who received the AstraZeneca vaccine, and who subsequently developed VITT. Two suffered clotting in their legs and the third had clots blocking arteries and veins inside their brain.
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial led by Washington University School of Medicine in St. Louis. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer.
Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.
A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning in a deadly metastatic form, according to results published in The New England Journal of Medicine. The immunotherapy nivolumab was used as an adjuvant therapy, which is given after surgery in the hopes of maximizing its effectiveness.
A new paper describes how a framework called "designing for value" was used to re-imagine the referral system of patients from primary care doctors to psychiatrists. The results seems to be an improved experience for patients, primary care doctors, and psychiatrists who participated in the model.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right